I will periodically be sharing updates and perspectives on various aspects of our business that I believe are helpful to stakeholders.
By: Faith Ashmore Benzinga Staff Writer May 8, 2024 Over 6.7 million Americans aged 65 and older are living with Alzheimer’s disease (AD) and this number is predicted to grow to 13.8 million by 2060. AD is the sixth leading cause of death
Phase 2 interim results Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively. The results indicate that IGC-AD1 clinically reduced agitation
POTOMAC, Md., April 16, 2024–(BUSINESS WIRE)–IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer’s
As of 2023, the estimated number of Americans living with Alzheimer’s disease was 6.7 million. However, a lesser-known subsection of Alzheimer’s is Agitation in dementia from Alzheimer’s Disease (AAD).
Potomac, MD, March 20, 2024 – IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in
Potomac, MD, February 23, 2024-IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets LLC (Ascendiant) has issued an analyst coverage research report on the Company’s common stock. A copy of the analyst
The company anticipates this milestone to facilitate approvals in other countries including the U.S. and Europe.
Periodic updates and perspectives on various aspects of our business.